Shares of Supreme, which trades on Toronto’s Venture Exchange and via an OTC ticker in the US, were up about 0.4% in early trading.

“We are excited to be entering into this agreement with Tilray, an organisation – like Supreme Cannabis – that focuses on the end user and demands leading quality assurance standards,” John Fowler, Supreme’s president, said in a press release.

“Tilray has built an industry-leading global medical distribution platform, which has resulted in robust demand for high quality cannabis products. We are happy to provide 7ACRES premium products alongside Tilray’s well-regarded and existing lineup to support medical patients around the world.”

Tilray’s medical-marijuana program has been a source of significant rallies for its stock price amid the 535% rise since its July initial public offering. Announcements of supplying CBD treatments in California and Australia have sent the stock on similar jumps the days they were announced.

Trials like the one in California are “a positive for both TLRY and the broader cannabis stock universe,” Vivien Azer, an analyst at Cowen, said at the time. “As additional medical applications and improved government support add another domino to future legalization in the U.S.”